Navigation Links
HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device Day
Date:9/19/2011

FRAMINGHAM, Mass. and SYDNEY, Sept. 19, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Lazard Capital Markets 3rd Annual Circulatory Assist Device Day at 1:55 p.m. ET on Thursday, September 22, 2011.  The one-day conference is being held at the Langham Hotel in Boston.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  A replay of the webcast will be available at the site after the presentation.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® Pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are register
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. HeartWare International Reports Third Quarter Revenues of $7.5 Million
5. HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
6. HeartWare to Present at the UBS 2010 Global Life Sciences Conference
7. HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
8. HeartWare to Report Financial Results for Third Quarter of 2010
9. HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
10. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
11. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014   Hospira, Inc. ... of injectable drugs and infusion technologies, today announced that ... Annual Healthcare Conference on Wednesday, Jan. 14, 2015, in ... scheduled to begin at 10:30 a.m. Pacific time on ... all interested parties through a live audiocast accessible via ...
(Date:12/19/2014)...  Monarch America Inc. (OTCQB: CANK) ("Monarch America" or ... provide this review of the Company,s recent achievements and ... "Over this past year, we achieved many of our ... to say that Monarch America is in a stronger ... been," stated Eric Hagen , CEO of Monarch ...
(Date:12/19/2014)... 2014 Somewhere between dropping five pounds and ... But Audicus , a next-generation hearing aids company, ... year. Hearing loss is the third most ... it is often unaddressed. Forty-eight million Americans have hearing ... aid, mainly due to price. Hearing aids traditionally cost ...
Breaking Medicine Technology:Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Audicus Will Help People Resolve to Hear Better in 2015 2
... DIEGO, Aug. 8, 2011 CareFusion Corp. (NYSE: ... results for the quarter and fiscal year ended June 30, ... Prevention businesses, gross margin expansion and the benefit of strong ... earnings for the quarter and for the year," said Kieran ...
... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... June 30, 2011. Quarterly Financial Highlights ... revenue for NUEDEXTA® of $2.2 million Cash, cash equivalents, and ... "I am thrilled with the progress we are making ...
Cached Medicine Technology:CareFusion Reports Fourth Quarter and Fiscal 2011 Results 2CareFusion Reports Fourth Quarter and Fiscal 2011 Results 3CareFusion Reports Fourth Quarter and Fiscal 2011 Results 4CareFusion Reports Fourth Quarter and Fiscal 2011 Results 5CareFusion Reports Fourth Quarter and Fiscal 2011 Results 6CareFusion Reports Fourth Quarter and Fiscal 2011 Results 7CareFusion Reports Fourth Quarter and Fiscal 2011 Results 8CareFusion Reports Fourth Quarter and Fiscal 2011 Results 9CareFusion Reports Fourth Quarter and Fiscal 2011 Results 10CareFusion Reports Fourth Quarter and Fiscal 2011 Results 11CareFusion Reports Fourth Quarter and Fiscal 2011 Results 12CareFusion Reports Fourth Quarter and Fiscal 2011 Results 13CareFusion Reports Fourth Quarter and Fiscal 2011 Results 14CareFusion Reports Fourth Quarter and Fiscal 2011 Results 15Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 2Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 3Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 4Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 5Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 6Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 7Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 8
(Date:12/21/2014)... 2014 Parker & Sons, Inc. a ... plumbing and other similar home contractor services announces a ... to its expert contracting services. The company is considered ... been serving Arizona for well over 40 years. Parker ... best in quality customer service to the residents and ...
(Date:12/21/2014)... 21, 2014 As testosterone therapy ... attacks, stroke and blood clots from using testosterone products ... new study shows that the male hormone testosterone may ... a study published in the Proceedings of the National ... examined a group of male rats with naturally occurring ...
(Date:12/20/2014)... is a professional company offering many kinds of ... its new engineered bamboo flooring collection, and announced a ... BambooIndustry.com’s customers come from many countries in the world: ... CEO of the company, the global bamboo flooring market ... years, and the demand for eco-friendly bamboo flooring products ...
(Date:12/20/2014)... NY (PRWEB) December 20, 2014 An ... healthcare sector have benefited the Massage Services ... discretionary characteristics of industry products, the anticipated 1.0% annualized ... period has provided consumers with the means to afford ... have received a massage in a given year has ...
(Date:12/20/2014)... holidays can be anything but joyous for people with ... and other allergy triggers. "The dust from the ... away in dank basements or dusty attics is triggering ... Shah, an affiliate faculty member at Loyola University Chicago ... Shah, who is also an allergist at Gottlieb ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Holiday Trimmings Can Trigger Allergies 2
... , , ... Department of Health recently designated Children,s Hospitals and Clinics of ... Children,s of Minnesota has the sixth busiest pediatric emergency department ... already treats around 450 trauma cases each year. Children,s ...
... men who opt out of aggressive treatment , MONDAY, ... for their early prostate cancer are not especially anxious ... , The evidence seems to contradict the assumption that ... patients, according to Dr. Roderick van den Bergh, of ...
... , , PHOENIX, July 27 ... set to open their first-ever mall location on July 31st. ... E. Village Way), will join nine other California locations in Brea, ... Tustin along with 26 locations in other regions. New locations ...
... , LAKE FOREST, Ill., July 27 Kirby ... industry,s first and only compact, fully-automated dispensing system . ... that handles all the functionality of a super-sized robotic dispenser, but in ... The KL60 is sized and priced for any retail pharmacy ...
... , , RADNOR, ... been selected as the NIMH Outreach Partner for the state ... Partners in each state, Puerto Rico and the District of ... are over 80 National Partners, including professional, consumer, advocacy, and ...
... , WASHINGTON and BALTIMORE, July 27 ... it, Congress should double the $5 billion currently budgeted for treatment ... and analyst Zoe Pagonis. They assert that "increasing drug treatment to ... an extraordinarily rational policy shift." , , ...
Cached Medicine News:Health News:Children's Hospitals and Clinics of Minnesota Receive Level III Trauma Designation 2Health News:Children's Hospitals and Clinics of Minnesota Receive Level III Trauma Designation 3Health News:Most Not Worried by Delayed Prostate Cancer Therapy 2Health News:Sprouts Farmers Market Sprouts New Location in Orange 2Health News:Kirby Lester's New KL60: The Pharmacy Industry's First and Only Compact, Fully-Automated Dispensing System 2Health News:Feeling Blue Suicide Prevention Council Partners With the National Institute of Mental Health 2Health News:Ex- White House Drug Spokesman Urges 'Double Drug Treatment'; Bob Weiner and Policy Analyst Zoe Pagonis Highlight 'Drug War's Wrong Focus' 2
... HEp-2000 ANA uses a patented HEp-2 ... to increase the sensitivity to SS-A/Ro autoantibodies, ... Several independent studies have been published worldwide ... increased sensitivity to SS-A/Ro autoantibodies when used ...
... The ANA and ENA assays ... patients negative for antinuclear antibodies, which ... diseases such as Systemic lupus erythematosus ... disease, progressive systemic sclerosis, scleroderma, polymyositis, ...
... The ANA and ENA assays can ... negative for antinuclear antibodies, which are ... such as Systemic lupus erythematosus (Lupus), ... progressive systemic sclerosis, scleroderma, polymyositis, dermatomyositis, ...
... Indirect Fluorescence Assay (IFA) for IgG ... for the qualitative and semi-quantitative detection ... in human serum. Detection of ANA ... an aid in the diagnosis of ...
Medicine Products: